READ OUR LATEST NEWS
Recent News
October 19, 2023
35Pharma Announces Oral Presentation Demonstrating Fat-Selective Weight Loss with HS235 at Obesity Week 2023
Montreal, QC, Canada (Oct. 16, 2023) – 35Pharma, a biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics to treat cardiopulmonary and cardiometabolic diseases, today presented results from its HS235 program at Obesity Week in Dallas, TX, USA (Oct. 14 – 17, 2023). HS235 is a potent and multi-specific trap targeting Activin and GDF ligands, including myostatin, which […]
March 5, 2023
35Pharma Announces Oral Presentation Featuring its Novel Activin and GDF Trap HS135 at the American College of Cardiology’s 72nd Annual Scientific Session (ACC)
Montreal, Canada (Mar. 5, 2023) – 35Pharma, a biopharmaceutical company that designs and develops biologics for cardiopulmonary and metabolic diseases, today reported preclinical results from its HS135 program in an oral presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, USA (Mar. 4 – 6, […]
November 7, 2022
35Pharma Presents New Preclinical Results for HS135, a Novel Activin and GDF Ligand Trap, at AHA 2022
Montreal, QC, Canada (Nov. 7, 2022) – 35Pharma, a biopharmaceutical company that designs and develops innovative biologics for cardiopulmonary diseases, today presented new preclinical results from its HS135 program at the 2022 American Heart Association Scientific Sessions (“AHA 2022”) in Chicago, IL, USA (Nov. 5 – 7, 2022). TGF-beta superfamily growth factors activin A and GDF-8 are validated targets […]
